Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance)
- 631 Downloads
Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting toxicity caused by several chemotherapeutic agents. Currently, CIPN is managed by empirical dose modifications at the discretion of the treating physician. The goal of this research is to quantitate the dose-CIPN relationship to inform the optimal strategies for dose modification. Data were obtained from the Cancer and Leukemia Group B (CALGB) 40502 trial, a randomized phase III trial of paclitaxel vs. nab-paclitaxel vs. ixabepilone as first-line chemotherapy for locally recurrent or metastatic breast cancer. CIPN was measured using a subset of the Functional Assessment of Cancer Therapy-Gynecologic Oncology Group Neurotoxicity (FACT-GOG-NTX) scale. A kinetic-pharmacodynamic (K-PD) model was utilized to quantitate the dose-CIPN relationship simultaneously for the three drugs. Indirect response models with linear and Smax drug effects were evaluated. The model was evaluated by comparing the predicted proportion of patients with CIPN (score ≥8 or score ≥12) to the observed proportion. An indirect response model with linear drug effect was able to describe the longitudinal CIPN data reasonably well. The proportion of patients that were falsely predicted to have CIPN or were falsely predicted not to have CIPN was 20% or less at any cycle. The model will be utilized to identify an early time point that can predict CIPN at later time points. This strategy will be utilized to inform dose adjustments to prospectively manage CIPN. Clinicaltrials.gov ID: NCT00785291
KEY WORDSCIPN ixabepilone K-PD model nab-paclitaxel paclitaxel
Compliance with Ethical Standards
Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA031946, U10CA033601, U10CA180821 and U10CA180882 (to the Alliance for Clinical Trials in Oncology), U10CA025224, U10CA032291, U10CA041287, U10CA077651, U10CA108068, U10CA138561, U10CA180790, U10CA180791, 5UG1CA189830, U10CA180836, and U10CA180867. Manish R. Sharma was also supported by K12CA139160 from the National Cancer Institute, by a Young Investigator Award from the Cancer Research Foundation, and by K23GM112128 from the National Institute of General Medical Sciences of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
- 3.Hershman DL, Lacchetti C, Dworkin RH, Smith EML, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941–67.CrossRefPubMedGoogle Scholar
- 15.Joerger M, Pawel JV, Kraff S, Fischer JR, Eberhardt W, Gauler TC, et al. Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2016;27(10):1895–902.CrossRefPubMedGoogle Scholar
- 19.Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Leung E, et al. Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol. 2015;33(21):2361–9.CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Presribing information of Paclitaxel. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf . Accessed on 26th Aug 2016.
- 26.Presribing information of Ixempra. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022065s006lbl.pdf. Accessed on 26th Aug 2016.
- 27.Presribing information of Nab-paclitaxel. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021660s041lbl.pdf. Accessed on 26th Aug 2016.
- 32.Pillai G, Gieschke R, Goggin T, Jacqmin P, Schimmer RC, Steimer JL. A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. Br J Clin Pharmacol. 2004;58(6):618–31.CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Barrett JS, Hirankarn S, Holford N, Hammer GB, Drover DR, Cohane CA, et al. A hemodynamic model to guide blood pressure control during deliberate hypotension with sodium nitroprusside in children. Front Pharmacol. 2015;6(July):1–10.Google Scholar
- 36.Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol. 2010;3(6):535–46.Google Scholar
- 39.Ando M, Yonemori K, Katsumata N, Shimizu C, Hirata T, Yamamoto H, et al. Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly in Japanese patients with solid tumors and metastatic breast cancer. Cancer Chemother Pharmacol. 2012;69:457–65.CrossRefPubMedGoogle Scholar